Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
Conditions
Atrial Fibrillation (AF)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
SEC Clinical Research, Dothan, Alabama, United States
Mission Cardiovascular Research Institute, Fremont, California, United States
National Institute of California Heart and Vein Specialists, Huntington Beach, California, United States
Profound Research LLC at Southern California Heart Specialists, Pasadena, California, United States
Cardiology Associates Medical Group, Ventura, California, United States
Interventional Cardiology Medical Group, West Hills, California, United States
South Florida Research Organization LLC, Medley, Florida, United States
Sec Clinical Research, Pensacola, Florida, United States
Clinical Site Partners, LLC DBA Flourish Research, Winter Park, Florida, United States
NSC Research, Inc, Johns Creek, Georgia, United States
Monroe Research, LLC, West Monroe, Louisiana, United States
Profound Research, Millennium Cardiology, Farmington Hills, Michigan, United States
AA Medical Research Center (MRC), Flint, Michigan, United States
K&R Research LLC, Marion, Ohio, United States
AnMed Health, Anderson, South Carolina, United States
PharmaTex Research, Amarillo, Texas, United States
Southwest Family Medicine Associates, Dallas, Texas, United States
Texas Institute of Cardiology PA, McKinney, Texas, United States
Study leads
Clinical Trial Management
Study Director
Regeneron Pharmaceuticals